View Exam | PowerPak

1. Which of the following molecules block BOTH vascular endothelial growth factor (VEGF) and angiopoietin 2 (ANG-2)?

A. Faricimab B. Aflibercept C. Bevacizumab D. Ranibizumab E. Unsure

2. Which of the following is not a risk associated with intravitreal injections?

A. Endophthalmitis (infection) B. Cataract C. Discoloration of the sclera D. Elevated intraocular pressure E. Retinal detachment F. Unsure

3. What is the leading cause of blindness in patients who have diabetes?

A. Proliferative diabetic retinopathy B. Diabetic macular edema C. Cataract D. Neovascular glaucoma E. Unsure

4. Which of the following is a major component of real-world observational studies?

A. Strict patient monitoring B. Rigorous data collection C. High medication adherence D. Use routine clinical care as a monitoring measurement E. High data quality and internal validity F. Unsure

5. Which of the following would not be a factor in improving patient adherence to treatment or outcomes for AMD or DME treatment?

A. Explain therapy requirements (frequent visits), cost, and possible adverse effects B. Shorten the time interval between injections C. Describe expectations of therapy D. Monitor therapy safety and efficacy E. Discuss vision improvement expectations F. Unsure

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following molecules block BOTH vascular endothelial growth factor (VEGF) and angiopoietin 2 (ANG-2)?

2. Which of the following is not a risk associated with intravitreal injections?

3. What is the leading cause of blindness in patients who have diabetes?

4. Which of the following is a major component of real-world observational studies?

5. Which of the following would not be a factor in improving patient adherence to treatment or outcomes for AMD or DME treatment?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following molecules block BOTH vascular endothelial growth factor (VEGF) and angiopoietin 2 (ANG-2)?

2. Which of the following is not a risk associated with intravitreal injections?

3. What is the leading cause of blindness in patients who have diabetes?

4. Which of the following is a major component of real-world observational studies?

5. Which of the following would not be a factor in improving patient adherence to treatment or outcomes for AMD or DME treatment?

« Return to Activity

Customers who Purchased
this Activity also Purchased